mRNA 1195
Alternative Names: EBV therapeutic vaccine - Moderna Therapeutics; mRNA-1195Latest Information Update: 20 Dec 2024
At a glance
- Originator Moderna Therapeutics
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Epstein-Barr virus infections
Most Recent Events
- 16 Dec 2024 Moderna Therapeutics plans a phase II trial for Multiple sclerosis (IM) in December 2024 (NCT06735248)
- 03 Aug 2023 Moderna Therapeutics completes enrollment of a phase I trial in Epstein-Barr virus infections (In adults, In volunteers) in USA (IM) (NCT05831111)
- 05 Apr 2023 Phase-I clinical trials in Epstein-Barr virus infections (In adults, In volunteers) in USA (Parenteral) (NCT05831111)